Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis

Molecular Cancer Therapeutics

Volumn 6, Issue 12, 2007, Pages 3297-3306

  Zhu, Baohe ^a,b   Lu, Lei ^a   Cai, Weibin ^a   Yang, Xia ^a   Li, Chaoyang ^c   Yang, Zhonghan ^a   Zhan, Wenhua ^b   Ma, Jian Xing ^d   Gao, Guoquan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RECOMBINANT KALLIKREIN BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MICROVASCULATURE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; STOMACH CARCINOMA; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

ANIMALS; BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SERPINS; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37549012221     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0798     Document Type: Article

References (46)

1. Chao J, Chao L. Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe Seyler 1995;376:705-13.
2. Chao J, Chai KX, Chao L. Tissue kallikrein inhibitors in mammals. Immunopharmacology 1996;32:67-72.
3. Chao J, Miao RQ, Chen V, Chen LM, Chao L. Novel roles of kallistatin, a specific tissue kallikrein inhibitor,in vascular remodeling. Biol Chem 2001;382:15-21.
4. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002;100:3245-52.
5. Gao G, Shao C, Zhang SX, Dudley A, Fant J, Ma JX. Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia 2003;46:689-98.
6. Chai KX, Ma JX, Murray SR, Chao J, Chao L. Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem 1991;266:16029-36.
7. Chao J, Chai KX, Chen LM, et al. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 1990;265:16394-401.
8. van Gent D, Sharp P, Morgan K, Kalsheker N. Serpins: structure, function and molecular evolution. Int J Biochem Cell Biol 2003;35:1536-47.
9. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994;269:15957-60.
10. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
11. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-8.
12. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000;6:196-9.
13. Wang CR, Chen SY, Wu CL, et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 2005;52:1319-24.
14. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
15. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
16. Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost 1997;78:672-7.
17. Gao G, Ma JX. Tipping the balance for angiogenic disorders. Drug Discovery Today 2002;7:171-2.
18. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
19. Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol 2004;14:139-45.
20. Garcia M, Fernandez-Garcia NI, Rivas V,et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004;64:5632-42.
21. Streck CJ, Zhang Y, Zhou J, Ng C, Nathwani AC, Davidoff AM. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth. J Pediatr Surg 2005;40:236-43.
22. Ueda K, Iwahashi M, Nakamori M,et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res 2001;61:6158-62.
23. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
24. Song ZY, Wen SQ, Peng JP, Huang X, Qian KD. Significance of vascular endothelial growth factor expression and its correlation with inducible nitric oxide synthase in gastric cancer. World J Gastroenterol 2004;10:1250-5.
25. Yang X, Cheng R, Li C, et al. Kringle 5 of human plasminogen suppresses hepatocellular carcinoma growth both in grafted and xenografted mice by anti-angiogenic activity. Cancer Biol Ther 2006;5:399-405.
26. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
27. Faivre J, Forman D, Esteve J, Gatta G. Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer 1998;34:2167-75.
28. Cunningham SC, Kamangar F, Kim MP,et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg 2005;9:718-25.
29. Furukawa T, Fu X, Kubota T, Watanabe M, Kitajima M, Hoffman RM. Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res 1993;53:1204-8.
30. Chen VC, Chao L, Pimenta DC, Bledsoe G, Juliano L, Chao J. Identification of a major heparin-binding site in kallistatin. J Biol Chem 2001;276:1276-84.
31. Miao RQ, Chen V, Chao L, Chao J. Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol 2003;284:C1604-13.
32. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
33. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
34. Xie K, Wei D, Shi Q, Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 2004;15:297-324.
35. Mizokami K, Kakeji Y, Oda S, et al. Clinicopathologic significance of hypoxia-inducible factor 1α overexpression in gastric carcinomas. J Surg Oncol 2006;94:149-54.
36. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25.
37. Stoeltzing O, McCarty MF, Wey JS, et al. Role of hypoxia-inducible factor 1α in gastric cancer cell growth,an giogenesis, and vessel maturation. J Natl Cancer Inst 2004;96:946-56.
38. Kakeji Y, Koga T, Sumiyoshi Y, et al. Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res 2002;21:125-9.
39. Poon RT, Fan ST, Wong J. Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. Ann Surg 2003;238:9-28.
40. Tabernero J, Macarulla T, Ramos FJ, Baselga J. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005;16:1740-8.
41. Shishido T, Yasoshima T, Denno R, Sato N, Hirata K. Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP-470. Jpn J Cancer Res 1996;87:958-62.
42. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor-growth in vivo. Nature 1993;362:841-4.
43. Wood JM. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Medicina B Aires 2000;60 Suppl 2:41-7.
44. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
45. McDonald DM, Foss AJ. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 2000;19:109-20.
46. Chen LM, Chao L, Chao J. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci 1997;60:1431-5.